Beovu is a small-sized, single strand antibody fragment with enhanced tissue penetration and active drug binding, that delivers a high concentration of the anti-VEGF drug to the target area in the eyes of patients with wet AMD. Beovu allows for 3-month dosing intervals after a 3-month loading phase, which may offer benefit to patients on other anti-VEGF drugs that require four week dosing periods, and for which frequency of monthly injections creates a burden. In two Phase III clinical trials, Beovu was effective in half of the patients at a dosing interval of 12 weeks in between treatments; the other half required treatments at 8-week intervals.
On average, patients gained seven letters on the eye chart, and 30 percent of patients gained at least 15 letters. In the trials, Beovu given every 2-3 months was non-inferior to Eylea given every two months. In addition, those patients receiving Beovu had reduced central retina thickness, and less retinal fluid detectable by OCT imaging.
References